Evaluation of serum Inhibin-B in polycystic ovarian syndrome (PCOs), premature ovarian failure (POF) and related with obese infertility, Case-Control study
DOI:
https://doi.org/10.69923/ewnpb460Keywords:
Inhibin-B, Polycystic Ovarian Syndrome (PCOS), Premature Ovarian Failure (POF)Abstract
Infertility is the failure to become pregnant after 1 year or more of frequent, unprotected sexual intercourse without taking contraceptives. It has two categories primary and secondary infertility. study aimed to use Inhibin-B for the prognosis of polycystic ovarian syndrome (PCOs) and premature ovarian failure (POF) in female infertility patients. The study was designed A case-control study, including (120) females with a range of age (20-40) years, subdivided into two groups (60) healthy apparent females used as control, and (60) infertile females distributed between (37 PCOs), (23 POF). Inhibin-B serum was measured using an enzyme-linked immunosorbent assay (ELISA). The results showed that the BMI level of patients was (30.95 ± 3.42) as compared to control (27.9 ± 1.93). In PCOs according to age above and under (35 years) showed a significant increase (p≤0.0001) in Inhibin-B (273.55 ± 75.25), (234.91±52.43) respectively, and a decrease in POF (18.96 ±1.21). Inhibin-B (95% CI: 0.907 - 1.000; P-value: 0.001; Cutoff Point: 77.347; AUC: 95.417%) with Sensitivity to Specificity (91.667% - 98.333%); and Accuracy: 95.000%. The study concluded that the increase in the levels of serum Inhibin-B could be considered a useful indicator of the likelihood that a female of reproductive age will have PCOs and POF that are diagnosed by the Rotterdam standards.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal for Applied Science

This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The copyright of this article is retained by the author(s).
This article is published by the Iraqi Journal for Applied Science (IJAS) under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This license permits unrestricted use, distribution, reproduction, adaptation, and reuse of the work in any medium or format, including commercial use, provided that appropriate credit is given to the original author(s) and the source, a link to the license is provided, and any modifications are indicated.
Authors retain full copyright of their work and grant IJAS a non-exclusive license to publish, archive, preserve, and disseminate the article, including registration of metadata and Digital Object Identifiers (DOIs) through Crossref.
Any third-party material included in this article remains subject to its respective copyright and licensing conditions. Authors are responsible for obtaining all necessary permissions for such material before publication.
For complete details regarding copyright, licensing, permissions, and reuse, please refer to the journal's Copyright and Licensing Policy available on the IJAS website.
License: https://creativecommons.org/licenses/by/4.0/



